DRDO's drug was first used in human clinical study patients by Dr. A K Banerji at AIIMS, DELHI, along with Dr. Viney Jain, former director of INMAS LAB.
|
|
Dr. A.K. Banerji who served at AIIMS' neurosurgery department for 30
years, said the drug was reasonably effective on cancer. Report from The New Indian Express: The Oral anti-viral drug 2-deoxy-D-glucose (2-DG), developed by the DRDO and being addressed as a game-changer in the battle against COVID-19, was first used in a human clinical study on brain tumor patients by Dr. A.K. Banerji and Dr. Viney Jain. Both served greatly for a long time making them perfect ones to discuss the topic. Dr. Banerji, who served 30 years in AIIMS' neurology department told the media, that the drug was reasonably effective on cancer but could not comment on its efficacy on Covid-19 patients. He said, "We used the drug for brain cancer. I can tell you that it was reasonably effective. And we hoped that it would get approval for commercial production, but that didn't happen. But COVID is not CANCER. I don't want to make presumptions whether it will work for Covid-19 patients or not". 2-DG developed by DEFENCE RESEARCH AND DEVELOPED ORGANISATION's leading laboratory Institute of Nuclear Medicine and Allied Science (INMAS) in collaboration with Hyderabad-based Dr. Reddy's Laboratory, has been granted emergency approval by DRUG CONTROLLER GENERAL OF India (DCGI) for Covid treatment. It has been studied in over 200 clinical trials for the treatment of various cancers globally. "Components are the same as the drug, then and now. Dr. Jain, a friend of mine from AIIMS, was working at the DRDO laboratory. He had convinced me to use the drug on cancer patients, We have used it as a Radiation Sanitizer," Dr. Banerji said. Dr. Jain has joined the faculty as an assistant professor in the biophysics department of AIIMS in 1973 and played a crucial role in bringing the drug to India for the First Time. "It had to be imported from the US at that time was expensive. If we have to use it, it has to be pre-ordered. Then tho DRDO gave a patent to a firm in MP so that It could be commercially viable. But another company was competing for the same drug that became popular," Dr. AK Banerji said. DRDO's experiment on COVID patientsIn April 2020, INMAS-DRDO scientists had conducted experiments with the help of The Centre for Cellular and Molecular Biology and found that this molecule works effectively against Covid and inhibits Viral Growth. These successful attempts lead to Phase-III trials. That was conducted on 220 patients from December 2020 to March 2021 at 27 Covid Hospitals. |
You can either comment on the post or you can connect with us on TWITTER and INSTAGRAM
Thanks,
TEAM TTIN.
Comments
Post a Comment